“Harnessing Augmented AI to Optimize Drug Development”-湖南大学材料科学与工程学院


您的当前位置: 首页 > 科学研究 > 学术活动 > 正文

“Harnessing Augmented AI to Optimize Drug Development”

发布者:Dean Ho, Professor发布时间:2017-11-06浏览量:


  目:Harnessing Augmented AI to Optimize Drug Development

报告人:Dean Ho, Professor Co-Director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology



主持人:张世国 教授




Dr. Dean Ho is currently a Professor in the Division of Oral Biology and Medicine and Department of Bioengineering, Co-Director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology, and member of the Jonsson Comprehensive Cancer Center and California NanoSystems Institute at UCLA. He was previously an Associate Professor at Northwestern University in the Departments of Biomedical and Mechanical Engineering.

Dr. Ho and collaborators are developing novel personalized medicine technologies (Augmented AI) based on the field of Phenotypic Personalized Medicine (PPM) to optimize clinical efficacy and safety for several combination therapy indications.He co-led the first in-human trial to personalize and optimize combination therapy for the entire duration of care, an unprecedented achievement. Specifically, his team partnered with leading surgeons to dynamically administer immunosuppressive therapies to prevent liver transplant rejection using PPM. PPM-treated patients dramatically outperformed control arm patients across every metric of comparison and were discharged nearly one month earlier compared to control patients (Science Translational Medicine, 2016, Cover Article). As the Director of Project NDX, he pioneered the development of nanodiamond platforms for the marked enhancement of efficacy and safety of drug delivery and imaging (Science Translational Medicine, 2011, 2013, Cover Articles). Recently, Dr. Ho initiated a landmark first in-human clinical trial to validate a nanodiamond-biomaterial device to enhance root canal therapy (Clinicaltrials.gov: NCT02698163). Current, Dr. Ho is co-leading a first in-human oncologic combination therapy study to dynamically modulate multi-drug regimens (positive results already reported).

Dr. Ho has appeared on the National Geographic Channel Program “Known Universe” to discuss his discoveries in nanodiamond drug delivery and imaging. He also recently served as a panelist at the XPRIZE Future of Medicine and InnovFest Unbound events, and his achievements have been featured on CNN, The Economist, Forbes, Washington Post, NPR and other international news outlets. Dr. Ho has served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 22,000-member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors, as well as academic visionaries. In this capacity, he led a team of pharmaceutical and medical device executives that partnered with the SLAS professional team to expand SLAS into Asia and Europe, pursuing mergers and acquisitions opportunities and establishing offices in Shanghai and Brussels. As SLAS President, Dr. Ho established the Quantitative Bioscience Graduate Fellowship Program with a $1 million dollar earmark.

Dr. Ho was recently named a Fulbright Scholar. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Society for Laboratory Automation and Screening. He is also a recipient of the NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, V Foundation for Cancer Research V Scholar Award, IADR William J. Gies Award, IADR Young Investigator Award, and Distinguished Young Alumnus award of the UCLA School of Engineering. He is a co-founder of multiple companies that are commercializing his drug development technologies, and currently advises venture capital/global equities funds, and several startups.